Loading…
Elutia Inc. is projected to rise to $1.50 by 2027, a +33% move from its current price of $1.13. ELUT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.10 | $1.13 | $1.16 | 0.00% |
| May 30 | $1.09 | $1.13 | $1.17 | 0.00% |
| May 31 | $1.08 | $1.13 | $1.18 | +0.01% |
| Jun 1 | $1.07 | $1.13 | $1.19 | +0.01% |
| Jun 2 | $1.07 | $1.13 | $1.20 | +0.01% |
| Jun 3 | $1.06 | $1.13 | $1.20 | +0.01% |
| Jun 4 | $1.06 | $1.13 | $1.21 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.06 | $1.13 | $1.21 | +0.01% |
| Week 2 | $1.03 | $1.13 | $1.25 | +0.03% |
| Week 3 | $1.00 | $1.13 | $1.27 | +0.04% |
| Week 4 | $0.9853 | $1.13 | $1.30 | +0.06% |
| Week 5 | $0.9696 | $1.13 | $1.32 | +0.07% |
| Week 6 | $0.9556 | $1.13 | $1.34 | +0.09% |
| Week 7 | $0.9429 | $1.13 | $1.36 | +0.10% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Elutia Inc. is a healthcare company described as a commercial-stage company that focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular, and its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery.
Elutia also provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction, and ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents.
The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
Elutia Inc. (ELUT) is a healthcare stock with a current price of $1.16 and a market capitalization of $51.28M. It ranks 4581 by market cap. The stock shows a bullish technical backdrop, with a current RSI of 60 and near-term price action guided by moving averages and defined support/resistance levels.
A major floor 27.6% below — a decisive break under it would weaken the trend.
The nearest floor, 13.6% below — buyers have tended to step in here.
The nearest ceiling, 6.2% above — a clean break opens room to run.
A major ceiling 17.3% above — clearing it would confirm fresh momentum.
Key ELUT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ELUT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.16 | Sell | $1.14 | Sell |
| MA 10 | $1.11 | Buy | $1.12 | Buy |
| MA 20 | $1.07 | Buy | $1.10 | Buy |
| MA 50 | $1.09 | Buy | $1.08 | Buy |
| MA 100 | $1.04 | Buy | $1.07 | Buy |
| MA 200 | $1.06 | Buy | $1.24 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.58 | Neutral |
| Stoch RSI (14) | 56.17 | Neutral |
| CCI (20) | 75.30 | Neutral |
| Williams %R (14) | -34.83 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 11.88 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 65.17 | Neutral |
| TRIX (15) | 0.05 | Buy |
| Awesome (5,34) | 0.08 | Buy |
| Ultimate (7,14,28) | 65.98 | Neutral |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 1.17 | Sell |
| ADX (14) | 15.21 | Neutral |
| ATR (14) | 0.03 | Info |
The near-term technical picture is bullish, with RSI14 at 60 indicating positive momentum. The price is above both the SMA50 ($1.09) and the SMA200 ($1.07), suggesting constructive trend strength. Traders should note the defined near-term boundaries: support at $0.976 and resistance at $1.20, with the 30-day range spanning $0.9681 to $1.39.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.614 | $1.13 | $1.67 | 0% | Neutral | |
| $1.20 | $1.50 | $2.00 | +33% | Bullish | |
| $1.46 | $1.88 | $2.58 | +66% | Bullish | |
| $1.57 | $2.06 | $2.91 | +82% | Bullish | |
| $1.57 | $2.10 | $3.03 | +86% | Bullish | |
| $1.68 | $2.29 | $3.38 | +103% | Bullish | |
| $1.68 | $2.33 | $3.50 | +107% | Bullish | |
| $1.94 | $2.73 | $4.17 | +142% | Bullish | |
| $2.39 | $3.42 | $5.30 | +203% | Bullish | |
| $2.47 | $3.58 | $5.62 | +217% | Bullish | |
| $3.20 | $4.93 | $8.22 | +337% | Bullish | |
| $5.89 | $10.10 | $18.36 | +794% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.614 | $1.13 | $1.32 | +0.00% |
| June 2026 | $0.9361 | $1.10 | $1.32 | -2.81% |
| July 2026 | $0.9574 | $1.13 | $1.38 | +3.09% |
| August 2026 | $1.00 | $1.19 | $1.46 | +5.14% |
| September 2026 | $1.00 | $1.20 | $1.49 | +0.86% |
| October 2026 | $1.02 | $1.22 | $1.52 | +1.80% |
| November 2026 | $1.07 | $1.29 | $1.62 | +5.61% |
| December 2026 | $1.09 | $1.32 | $1.67 | +2.59% |
Click any year to see its month-by-month ELUT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ELUT is projected to trade between $0.614 and $1.67, averaging $1.13 — a potential gain of 0% from today's $1.13. A consolidation phase looks the most probable path here.
Elutia Inc.'s 2027 outlook centres on $1.50, within a $1.20 to $2.00 range. That is up +33% on the projected 2026 average. That marks a +33% change versus current levels. Momentum favours further upside here.
By 2028, ELUT could reach as high as $2.58, with a base case around $1.88 and support toward $1.46 — roughly +66% from $1.13. Buyers look set to stay in control over this stretch.
Expect ELUT to range from $1.57 to $2.91 through 2029. The $2.06 average target implies a +82% move from current prices. That is up +10% on the projected 2028 average. Momentum favours further upside here.
The ELUT price prediction for 2030 points to an average of $2.10 (low $1.57, high $3.03) — a potential gain of +86% on today's $1.13. Buyers look set to stay in control over this stretch.
In 2031, ELUT is projected to trade between $1.68 and $3.38, averaging $2.29 — a potential gain of +103% from today's $1.13. That is up +9% on the projected 2030 average. Momentum favours further upside here.
Elutia Inc.'s 2032 outlook centres on $2.33, within a $1.68 to $3.50 range. That is up +2% on the projected 2031 average. That marks a +107% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ELUT could reach as high as $4.17, with a base case around $2.73 and support toward $1.94 — roughly +142% from $1.13. Momentum favours further upside here.
Expect ELUT to range from $2.39 to $5.30 through 2034. The $3.42 average target implies a +203% move from current prices. That is up +25% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The ELUT price prediction for 2035 points to an average of $3.58 (low $2.47, high $5.62) — a potential gain of +217% on today's $1.13. Momentum favours further upside here.
In 2040, ELUT is projected to trade between $3.20 and $8.22, averaging $4.93 — a potential gain of +337% from today's $1.13. That is up +38% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Elutia Inc.'s 2050 outlook centres on $10.10, within a $5.89 to $18.36 range. That is up +105% on the projected 2040 average. That marks a +794% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ELUT today (≈ 884.955752 ELUT) could be worth
$8,940.87
+$7,940.87 (+794%) by 2050 · US Dollar
Based on the average projected ELUT price of $10.1 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ELUTwould be worth at today's price.
$1,000 invested in ELUT on May 27, 2025 (≈ 581.395339 ELUT) would be worth
$656.98
-$343.02 (-34.3%) today · 0.66× · US Dollar
Based on a ELUT entry price of $1.72 vs. today's $1.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.18 | $957.63 | -4.2% |
| 1 month ago | $1.02 | $1,107.84 | +10.8% |
| 3 months ago | $1.15 | $982.61 | -1.7% |
| 6 months ago | $0.612 | $1,846.41 | +84.6% |
| 1 year ago | $1.72 | $656.98 | -34.3% |
| All time (5.0y) ago | $12.37 | $91.35 | -90.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ELUT forecast.
Our base-case forecast reaches $2.30 around 2032.
Implied market cap at $2.30: $101.68M
The year-by-year forecast shows a bullish trajectory across the horizon. In 2026 the average price is $1.16 with an ROI of 0% and a Neutral sentiment. By 2027 the average rises to $1.53 with an ROI of 32.2% and a Bullish stance, and by 2028 the average is $1.94 with an ROI of 66.9% Bullish.
In 2029 the average is $2.10 with an ROI of 81% Bullish, and in 2030 the average is $2.12 with an ROI of 82.7% Bullish. The forecast continues to climb, with 2031 at $2.32 (ROI 99.7%), 2032 at $2.32 (ROI 100.3%), 2033 at $2.73 (ROI 135%), 2034 at $3.45 (ROI 197.1%), and 2035 at $3.56 (ROI 206.7%), all Bullish. Looking further out, 2040 shows an average of $4.90 with an ROI of 322.3% Bullish, and 2050 projects an average of $9.88 with an ROI of 751.6% Bullish.
These are estimates and not guarantees; outcomes depend on multiple factors and market conditions.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $2.12 with an ROI of 82.7% and a Bullish sentiment (min $1.57, max $3.09).
The forecast paints a Bullish path in later years with rising averages (e.g., $2.12 in 2030 and $9.88 in 2050) and meaningful ROIs, but the 2026 value shows an average of $1.16 with an ROI of 0% and the outlook remains subject to risk and uncertainty; these are estimates, not guarantees.
Yes, according to the forecast, the max values exceed $5 in several years: 2034 max $5.41 and 2035 max $5.67, with 2040 max $8.30 and 2050 max $18.31.
Current price is $1.16 and market cap is $51.28M. The stock rank is 4581.
Near-term support is $0.976 and resistance is $1.20, with a 30-day range from $0.9681 to $1.39.
Elutia Inc. Community Discussion
0Share your Elutia Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.